Bristol-Myers Squibb 2012 Annual Report Bristol-Myers Squibb  5 In this Special Report, we examine each area and introduce you to exam- ples of how our people continue to transform Bristol-Myers Squibb and  in so doing, help develop new possibilities for patients everywhere.  As we look to the future, we will need to focus our efforts across a number of essential areas: Today we stand on the frontiers of extraordinary new possibilities  for addressing significant unmet medical need. And while we have  come a great distance in the past several years to successfully  transform ourselves into a benchmark BioPharma company, there  are great opportunities to do even more. Most importantly, we have  and will continue to attract and retain the best people around the  world. And each day they come to work, they remain committed to  a single overriding mission: to help more patients prevail in their  fight against serious diseases. FRONTIERS OF SCIENCE THE Developing New Possibilities for Patients our competitive advantage to deliver  the promise of new medicines. • Extending the Reach of Our Medi - cines – Ensuring that more patients  around the world gain access to our leading medicines will help them prevail over their illnesses, create value for our shareholders and develop the resources required to invest in our future. • Ensuring a Robust R&D Pipeline  – In  addition to the diseases for which we  have medicines already available, we  continue to diversify and expand our  horizons in areas like hepatitis C, neu- rodegenerative disorders and fibrosis. • Creating a Culture of Continuous  Improvement  – Working smarter, better and faster will help us drive  • Committing to Responsible Citizen - ship  – Acting in a socially respon- sible, ethical and sustainable manner  is a commitment we must make and  act upon every day. • Developing Innovations on the  Frontiers of Medicine  – Cardiovas- cular disease, immuno-oncology  and diabetes are three leading areas  where we have recently introduced  new medicines and where we are  developing a pipeline of innovative  therapies that expand the frontiers of biomedical research.